FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema

FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema
Wed, 02 Dec 2009 15:45:00 -0600

The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).


Manage your FDA Subscriptions:


Fight Flu with Facts! Visit flu.gov. Call 800-232-4636. Text FLU to 87000.

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux